Gefapixant is a P2X3 antagonist that was recently studied in two phase 3 randomized controlled trials, COUGH-1 and COUGH-2, and is currently under regulatory review in Europe. In this interview, we were delighted to speak with Elena Kum (McMaster University, Hamilton, ON, Canada) around the aims, methodology and findings from her dose-response meta-analysis of gefapixant. […]

Air pollution has been linked to exacerbating and causing symptoms associated with respiratory diseases, particularly impacting patients with asthma, COPD and allergic disease. touchRESPIRATORY were delighted to speak with Prof. Claudia Traidl-Hoffmann (University in Augsburg, Germany) around the symptoms associated with exposure to air pollution, the impact of air pollution on existing respiratory conditions and […]

The phase 3 BOREAS study (NCT03930732) investigated the efficacy and safety of dupilumab for the treatment of chronic obstructive pulmonary disease with type 2 inflammation. It was a pleasure to talk with Prof. Klaus F. Rabe (University of Kiel, Germany) around the aims, design, inclusion criteria and findings from the phase 3 study and the […]

Dupilumab is an investigational monoclonal antibody that mitigates type 2 inflammation by blocking IL-4 and IL-13 receptors in patients with COPD. We were delighted to talk with Prof. Klaus F. Rabe (University of Kiel, Germany) around the unmet needs in the treatment of COPD, the association between type 2 inflammation and COPD exacerbations and the […]

The COVA study (NCT04472728) was a double-blind, placebo-controlled phase 2 to 3 study that investigated BIO101 for the prevention of respiratory deterioration in hospitalized COVID-19. touchRESPIRATORY were delighted to speak with Dr. Girish B. Nair (Beaumont Health, Royal Oak, MI, USA) around the mechanism of action of BIO101, the design, inclusion criteria and findings from […]

The US Bronchiectasis and NTM Research Registry is a centralized database for the study of adult patients with non-cystic fibrosis bronchiectasis. In this interview Dr. Mark Metersky (UConn Health, Farmington, CT, USA) discusses the current challenges in the diagnosis and management of bronchiectasis and NTM, the aims of the registry and how it could impact […]

The phase 2 WILLOW trial (NCT03218917) investigated the efficacy, safety, tolerability, and PK of brensocatib in patients with non-cystic fibrosis bronchiectasis. We were delighted to speak with Dr Mark Metersky (UConn Health, Farmington, CT, USA) to learn more around his subgroup analysis looking at brensocatib efficacy by disease severity. The abstract ‘Outcomes of Patients With […]

Idiopathic pulmonary fibrosis (IPF) is a serious chronic lung disease which results in symptoms such as shortness of breath and dry cough and is caused by fibrosis of the lungs. It was a pleasure to talk with Dr. Steven D. Nathan (Inova Fairfax Hospital, Falls Church, VA, USA) to discuss the incidence, prognosis and pathology of […]

The TETON program consists of two currently recruiting phase 3 randomized, double-blind, placebo-controlled studies that are investigating the efficacy and safety of inhaled treprostinil in idiopathic pulmonary fibrosis (NCT04708782, NCT05255991). It was a pleasure to talk with Dr. Steven D. Nathan (Inova Fairfax Hospital, Falls Church, VA, USA) around the aims and design of the TETON program […]